Accelerating Life- Changing Medicines

We are knowledgeable, confident and results-oriented experts who work with a sense of urgency to identify, acquire and accelerate development and delivery of transformative medicines for patients.

Recent News

ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to...

LOS ANGELES, Sept. 19, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of trans...

ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous T...

Rapid-fire Oral Presentation to Highlight Efficacy, Safety, and Quality of Life Outcomes LOS ANGELES, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage...

ACELYRIN, INC. to Participate in Upcoming Investor Conferences

LOS ANGELES, Aug. 22, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transf...

Icon1/3Icon
Acelyrin Test Tube Icon

Our Science

We are exploring innovative approaches in immunology where we have the opportunity to make a clinically meaningful difference for patients relative to standard of care.

Learn More
Acelyrin Team Icon

Meet Our Leadership

We are led by a team of veteran biopharma executives who bring exceptional track records of developing and commercializing transformative therapies.

Learn More

Courageous Caring

Guided by our key cultural value of Courageous Caring, and driven by a sense of urgency, we are building an innovative biopharma company that aims to invest in, develop and commercialize clinically meaningful therapies.

We Care as Scientists, and We Care as People
Who We Are

We Care as Scientists, and We Care as People

We have the right blend of scientific, medical, operational and corporate experience to identify, develop and commercialize treatments with the potential to dramatically transform patients’ lives.
Our Story Arrow purple
Our Work

Accelerating Transformative Therapies

We are actively investigating the potential of izokibep and lonigutamab in diseases where differentiated inhibition of validated targets may help to address unmet patient needs.
Careers

Join a team that Courageously Cares

ACELYRIN is building a biopharma company with a corporate culture of Courageous Caring - placing patients first and embracing the concept that all of us together are better than any one of us alone. We strive to address the most basic human needs: to live a productive life free from disease.
Learn More Arrow purple
Join a team that Courageously Cares